The company's SSi Mantra 3 robotic surgery system has already gained regulatory approvals in several countries. FDA approval is anticipated by late 2025 or early 2026.

The three-day event is now in its second year. Each day will feature late-breaking clinical trials focused on a different heart valve.

Even TAVR patients not treated using transfemoral access can typically go home the very next day. 

The EARLY TAVR clinical trial made a significant impact, paving the way for the FDA to approve multiple transcatheter heart valves for the treatment of asymptomatic patients. However, one cardiologist who participated in the trial has some serious concerns with how its findings were presented to the public. 

SCAI and other healthcare groups want changes made to how healthcare providers are paid after performing office-based lab procedures. "As much as we love delivering care as doctors, if we are losing money doing something, we cannot sustain it," one cardiologist explained. 

Patients treated with the Sapien 3 platform from Edwards Lifesciences and the Evolut platform from Medtronic were linked to more similarities than differences after six years. This was a single-center study, researchers noted, but it does provide an in-depth look at the safety and effectiveness of TAVR.

Sola is a rupture-resistant balloon catheter that uses laser energy to deliver 360-degree pressure with each pulse. It was designed to address limitations the company saw in current calcium-modification devices.

However, eligibility alone does not mean a patient will benefit from treatment.